Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-0027, Japan.
J Gastroenterol. 2013 Aug;48(8):951-65. doi: 10.1007/s00535-012-0690-0. Epub 2012 Oct 12.
In our previous study, we classified the radicality (R grading) of percutaneous radiofrequency ablation (RFA) therapy for single hepatocellular carcinoma (HCC) according to the extent of the ablated margin, and demonstrated that this grading system was useful for predicting local tumor progression (LTP) after RFA. The aim of this study was to measure the overall survival (OS), the recurrence free survival (RFS), and the distant recurrence (DR) rate for each R grade (A-D), and to examine the relationship between clinical outcome and R grading.
This study involved 368 patients with solitary HCC who had undergone RFA. The mean tumor diameter was 2.0 ± 0.7 cm. We calculated the post-RFA cumulative OS, RFS, and DR rate for each R grade and analyzed the factors contributing to clinical outcomes.
In the multivariate analysis, significant factors were as follows: tumor size >2 cm, serum albumin >3.5 g/dL, prothrombin time >70 %, HCC recurrence within 1 year, and R grading (grade A) in OS; cause of liver disease (hepatitis B), gamma glutamyl transpeptidase (GGT) >80 IU/L, platelet count >10 × 10(4)/mm(3), and R grading (grade A or B) in RFS; GGT >80 IU/L, platelet count >10 × 10(4)/mm(3), and R grading (grade A or B) in DR. In patients with sufficient Lipiodol accumulation (n = 219), very similar results were obtained. However, in patients with grade A and B (n = 232), R grade was not a significant independent factor linked to OS, although grade A patients had lower LTP rate.
Our proposed R grading system appears to be useful for predicting clinical outcomes after RFA.
在我们之前的研究中,我们根据消融边缘的范围对经皮射频消融(RFA)治疗单个肝细胞癌(HCC)的根治性(R 分级)进行了分类,并证明该分级系统有助于预测 RFA 后的局部肿瘤进展(LTP)。本研究的目的是测量每个 R 级(A-D)的总生存期(OS)、无复发生存期(RFS)和远处复发(DR)率,并检查临床结果与 R 分级之间的关系。
本研究纳入了 368 例接受 RFA 治疗的单发 HCC 患者。平均肿瘤直径为 2.0±0.7cm。我们计算了每个 R 级的 RFA 后累积 OS、RFS 和 DR 率,并分析了影响临床结果的因素。
在多变量分析中,以下因素具有显著意义:肿瘤直径>2cm、血清白蛋白>3.5g/dL、凝血酶原时间>70%、HCC 复发在 1 年内、R 分级(A级)在 OS 中;肝病病因(乙型肝炎)、γ-谷氨酰转肽酶(GGT)>80IU/L、血小板计数>10×10(4)/mm(3)和 R 分级(A级或 B 级)在 RFS 中;GGT>80IU/L、血小板计数>10×10(4)/mm(3)和 R 分级(A级或 B 级)在 DR 中。在具有足够碘油积聚的患者(n=219)中,得到了非常相似的结果。然而,在 R 分级为 A 和 B 的患者(n=232)中,R 分级不是与 OS 相关的独立显著因素,尽管 A 级患者的 LTP 率较低。
我们提出的 R 分级系统似乎可用于预测 RFA 后的临床结果。